share_log

Opinion: 7 penny stocks you can pick up for less than a dollar

Opinion: 7 penny stocks you can pick up for less than a dollar

意見:7 便士股票你可以拿起不到一美元
InvestorPlace ·  2021/07/13 10:27  · 觀點

Penny stocks have sprung into focus with the rise of meme stock trading. Penny stocks have shown a lot of bullish action in the past few months. The market has been volatile, but overall, investors are hopeful about the future. A lot of it can be attributed to the positive updates concerning the pandemic.

隨着Meme股票交易的興起,細價股迅速成為人們關注的焦點。在過去的幾個月裏,細價股表現出了大量的看漲行為。市場一直不穩定,但總的來説,投資者對未來抱有希望。這在很大程度上可以歸因於有關大流行的積極更新。

There are purely speculative penny stocks, while there are some with strong outlooks and fundamentals. Therefore, it’s imperative to choose wisely in adding value to your portfolio with penny stocks.

有純粹投機的細價股,也有前景和基本面強勁的股票。因此,在用細價股為你的投資組合增值時,明智地選擇是非常必要的。

There have been several positive developments concerning the pandemic. In the U.S., health conditions has declined rapidly in the past few months. This is mainly due to millions of vaccine doses that have been distributed. As a result, economic experts believe that the economy could rebound in the coming months. Factors such as low employment numbers and solid retail figures suggest that the future is bright. As a result, several penny stocks have been increasing in value.

關於這一大流行,出現了幾個積極的事態發展。在美國,健康狀況在過去幾個月裏迅速下降。這主要是由於已經分發了數百萬劑疫苗。因此,經濟專家認為,經濟可能在未來幾個月反彈。就業數據低迷和零售數據穩健等因素表明,前景是光明的。因此,一些廉價股的價值一直在上漲。

This list covers seven of the most promising penny stocks trading under a dollar at the time of writing:

這份名單涵蓋了在撰寫本文時交易價格低於1美元的7只最有前途的細價股:

Penny Stocks to Buy: Cyren (CYRN)

值得買入的細價股:CyREN

$CYREN Ltd(CYRN.US)$ is a small-cap cybersecurity company operating as a software as a service company. It focuses on threat intelligence and email security services. Despite its minuscule size in its industry, it has a customer base that includes heavy hitters like $Microsoft Corp(MSFT.US)$ and $Alphabet Inc-CL C(GOOG.US)$. However, from a fundamentals perspective, it isn’t nearly as eye-catching as its peers, but it has a substantial growth runway ahead, making CYRN a worthwhile bet.

$CYREN有限公司(CYRN.US)$是一家小型網絡安全公司,以軟件即服務的形式運營。它專注於威脅情報和電子郵件安全服務。儘管它在行業中的規模微不足道,但它的客户基礎包括重量級人物,如$微軟(微軟美國)$$Alphabet-CL C(谷歌)$。然而,從基本面的角度來看,它遠不像其他同行那樣引人注目,但它前面有一條可觀的增長跑道,這使它成為一個值得押注的公司。

Earnings results have largely been underwhelming, but it has a few growth initiatives resulting in expansion as we advance. One such product is Cyren Inbox Security, a cloud-based email security offering that provides automated response and remediation for various security threats. Revenues from the product nearly tripled from the second quarter in 2020. Moreover, the company added several new midsized and large enterprises to its customer base in its most recent quarter.

盈利業績在很大程度上並不令人印象深刻,但它有一些增長舉措,導致了隨着我們的進步而擴張。Cyren Inbox Security就是這樣的產品之一,這是一款基於雲的電子郵件安全產品,可為各種安全威脅提供自動響應和補救。與2020年第二季度相比,該產品的收入幾乎增長了兩倍。此外,該公司在最近一個季度的客户羣中新增了幾家大中型企業。

Oragenics (OGEN)

造山學(Ogen)

$Oragenics Inc(OGEN.US)$ is small-size development-stage biotech, which develops therapeutics for infectious diseases. It currently has two pre-IND therapeutics in its product pipeline, which hopes could change its fortunes. These products aim to combat infectious diseases such as C. difficile and health conditions and could be massive money-spinners for OGEN stock.

$Oragenics Inc.(OGEN.US)$是一種小型開發階段的生物技術,開發傳染病的療法。該公司目前有兩種前IND療法在產品流水線中,希望能改變其命運。這些產品旨在對抗艱難梭菌等傳染病和健康狀況,可能是Ogen股票的鉅額搖錢樹。

The company is in a relatively secure financial position, with its cash reserves at $36.5 million as of the first quarter this year. It doesn’t expect meaningful revenues before 2024, though, and outlines an expected cash burn of $28 million through the second quarter of 2022. Therefore, it would need funding at some stage in the next year to see its projects past the finish line. IND’s for both its pre-IND therapeutics will be submitted in the fourth quarter this year. Hence, there’s a lot to look forward to with OGEN stock this year.

該公司的財務狀況相對穩定,截至今年第一季度,其現金儲備為3650萬美元。不過,該公司預計在2024年之前不會有可觀的收入,並概述了到2022年第二季度預計將消耗2,800萬美元的現金。因此,它需要在明年的某個階段獲得資金,才能看到其項目超過終點線。這兩種IND前療法的IND將在今年第四季度提交。因此,今年Ogen的股票有很多值得期待的地方。

Penny Stocks to Buy: Great Panther Mining (GPL)

值得買入的細價股:大豹礦業(GPL)

Canadian Gold Miner, $Great Panther Mining Ltd(GPL.US)$ had been posting triple-digit revenue growth numbers before the pandemic kicked in. Naturally, the pandemic has pushed it back several steps by creating cost issues, lowering reserves and delaying its projects. Despite its shortcomings, GPL stock is a gold-mining play that can rebound in the coming months and trades at under two times forward sales.

加拿大黃金礦工,$Great Panther Mining Ltd(GPL.US)$在大流行開始之前,一直公佈了三位數的收入增長數字。自然,疫情造成了成本問題,降低了儲備,並推遲了項目,從而推遲了幾個步驟。儘管存在缺陷,但GPL的股票是一個淘金者,可以在未來幾個月反彈,其預期市盈率不到兩倍。

In its first quarter, the company did well to expand its margins and fortify its balance sheet. It reduced its debt position by a massive $27.6 million, ending the quarter with over $40 million in cash. Moreover, its net loss was at $0.3 million compared to $40.5 million in the first quarter of 2020. However, gold production has dropped considerably in its Tucano mine and its silver operations in Topia and GMC. Things are a bit dicey with the company, but you can afford to be a little speculative with GPL stock, given its throw-away price.

在第一季度,該公司在擴大利潤率和鞏固資產負債表方面表現良好。該公司大幅削減了2,760萬美元的債務,本季度末現金超過4,000萬美元。此外,該公司的淨虧損為30萬美元,而2020年第一季度為4050萬美元。然而,其Tucano礦以及託皮亞和GMC的白銀業務的黃金產量大幅下降。這家公司的情況有點不確定,但考慮到它的一次性價格,你可以對GPL的股票進行一點投機。

Evofem Biosciences (EVFM)

Evofem生物科學(EVFM)

$Evofem Biosciences Inc(EVFM.US)$ is a biopharma company involved in the development and commercialization of products that cater to the unmet needs in women’s reproductive health. Its core product is called Phexxi, which is a vaginal gel used to prevent pregnancy. The product has a market of over $1 billion in the U.S., with plenty of room to grow and power EVFM stock in the future.

$Evofem Biosciences Inc.(EVFM.US)$是一家生物製藥公司,從事滿足婦女生殖健康方面未得到滿足的需求的產品的開發和商業化。它的核心產品是Phexxi,這是一種用於避孕的陰道凝膠。該產品在美國的市場價值超過10億美元,未來有很大的增長空間和支持EVFM的股票。

The company is also working on a product called the EVO100. It’s essentially an antimicrobial vaginal gel to prevent Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. If everything goes according to plan, it would be available for sale by 2024. In the meantime, Evofem will continue to win big with Phexxi and expand to other countries.

該公司還在開發一款名為EVO100的產品。它本質上是一種抗菌陰道凝膠,用於預防女性感染沙眼衣原體和淋球菌。如果一切按計劃進行,它將在2024年上市銷售。與此同時,Evofem將繼續憑藉Phexxi大獲全勝,並向其他國家擴張。

Penny Stocks to Buy: Gran Tierra Energy (GTE)

值得買入的細價股:Gran Tiera Energy(GTE)

$Gran Tierra Energy Inc(GTE.US)$ is an intermediate oil producer and explorer that has struggled to unlock value for investors for years. Reasons for this include its massive debt load, weak oil prices, and ineffective merger and acquisition activity. The health conditions-ridden year 2020 didn’t do it any favors either, as oil prices tanked to historic lows. However, the outlook is becoming increasingly positive for crude oil, leading to higher Brent pricing and a considerable upside for GTE stock.

$Gran Tiera Energy Inc.(GTE.US)$是一家中等規模的石油生產商和勘探商,多年來一直難以為投資者釋放價值。原因包括其龐大的債務負擔、疲軟的油價以及無效的併購活動。隨着油價跌至歷史低點,飽受健康狀況困擾的2020年也沒有給它帶來任何好處。然而,原油前景正變得越來越樂觀,導致布倫特原油價格上漲,GTE庫存也有相當大的上行空間。

Outlook for the Brent price has improved drastically this year. Investment bank Goldman Sachs predicts that Brent could potentially hit $80 per barrel during the summer. The bullishness, supported by vaccine rollout and the expanding U.S. economic recovery, saw Brent gain a massive 70%. Moreover, with improvements in the political climate in Columbia, Gran Tierra will not only meet its budget targets but could exceed its guidance this year.

今年,布倫特原油價格的前景已大幅改善。投資銀行高盛(Goldman Sachs)預測,布倫特原油價格可能在夏季觸及每桶80美元。在疫苗推出和美國經濟復甦不斷擴大的支持下,布倫特原油價格大幅上漲了70%。此外,隨着哥倫比亞政治氣候的改善,Gran Tiera不僅將實現其預算目標,而且今年可能會超過其指導方針。

Zomedica (ZOM)

佐梅迪卡(Zomedica)

$Zomedica Corp(ZOM.US)$ is a small-cap biopharma company that aims to be a disruptor in animal healthcare diagnostics. It launched its first product called Truforma, a veterinary diagnostic tool that can perform five diagnostic tests for adrenal and thyroid conditions in cats and dogs. Although it hasn’t generated any meaningful sales yet, ZOM stock has quite the potential to grow immensely in the future.

$Zomedica Corp(ZOM.US)$是一家小型生物製藥公司,旨在成為動物保健診斷領域的顛覆者。該公司推出了第一款名為Truforma的產品,這是一種獸醫診斷工具,可以對貓和狗的腎上腺和甲狀腺狀況進行五種診斷測試。儘管Zom還沒有產生任何有意義的銷售,但它的股票在未來有相當大的增長潛力。

The veterinary diagnostics field alone is an industry and can grow over 9.4% to $3.9 billion on an annual basis through 2026. Hence, if the company can gain only a fraction of this market, it would be looking at massive revenues down the road. It’s an incredible tool for veterinarians and can potentially gain substantial traction in the foreseeable future.

僅獸醫診斷領域就是一個行業,到2026年,該領域的年增長率可超過9.4%,達到39億美元。因此,如果該公司只能獲得這個市場的一小部分,它將着眼於未來的鉅額收入。對於獸醫來説,這是一個令人難以置信的工具,在可預見的未來,它可能會獲得巨大的吸引力。

Penny Stocks to Buy: Gold Standard Ventures (GSV)

值得買入的細價股:黃金標準風險投資公司(GSV)

$Gold Standard Ventures Corp(GSV.US)$ has been one of the worst-performing gold stocks in the past year. This is surprising considering its ownership of a sizeable land package in Nevada. The package is home to 2.75 million ounces of gold with an average grade of just one gram per gold ton.

$Gold Standard Ventures Corp(GSV.US)$一直是過去一年表現最差的黃金類股之一。考慮到它在內華達州擁有相當大的地塊,這是令人驚訝的。該包擁有275萬盎司黃金,平均品位僅為每黃金噸1克。

However, several developments have been off-late, which could point to a remarkable upside for GSV stock. The company has recently had a major management shake-up and capital raises to bolster its treasury. Hence, these developments could potentially lift its stock which is trading at an insanely low price.

然而,有幾個進展來得晚,這可能表明GSV的股票有一個顯著的上行空間。該公司最近進行了一次重大的管理層改組,並籌集了資金以充實其國庫。因此,這些進展可能會提振其股價極低的股票。

No content on the website shall be considered a recommendation or solicitation for the purchase or sale of securities, futures, or other financial products. All information and data on the website are for reference only and no historical data shall be considered as the basis for predicting future trends.

網站上的任何內容不得被視為購買或銷售證券、期貨或其他金融產品的推薦或邀約。網站上的所有信息和數據僅供參考,歷史數據不得作為預測未來趨勢的依據。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論